LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

10.98 -2.05

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.72

Max

11.13

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M -20M
Pardavimai	5.9M 40M
Pelno marža	-49.569
Darbuotojai	184
EBITDA	16M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+90.19% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	455M 1.2B
Ankstesnė atidarymo kaina	13.03
Ankstesnė uždarymo kaina	10.98

Naujienos nuotaikos

By Acuity

50%

160 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-12 23:57; UTC

Karštos akcijos

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

2026-02-12 23:35; UTC

Uždarbis

Pagrindinės rinkos jėgos

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

2026-02-12 23:28; UTC

Uždarbis

Applied Materials Profit Rises on Soaring AI Demand -- Update

2026-02-12 21:47; UTC

Uždarbis

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

2026-02-13 00:00; UTC

Rinkos pokalbiai

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

2026-02-12 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

2026-02-12 23:38; UTC

Rinkos pokalbiai

Gold Steady; Could Undergo Technical Recovery -- Market Talk

2026-02-12 23:33; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

2026-02-12 23:09; UTC

Rinkos pokalbiai

South32's Hermosa Review Stokes Spending Fears -- Market Talk

2026-02-12 22:55; UTC

Uždarbis

Karštos akcijos

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

2026-02-12 22:46; UTC

Rinkos pokalbiai

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

2026-02-12 22:23; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Net $1.52B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

2026-02-12 22:00; UTC

Uždarbis

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

2026-02-12 21:57; UTC

Uždarbis

XP 4Q Rev BRL4.95B >XP

2026-02-12 21:52; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-12 21:47; UTC

Uždarbis

Morningstar 4Q Rev $641M >MORN

2026-02-12 21:39; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:38; UTC

Uždarbis

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

90.19% į viršų

12 mėnesių prognozė

Vidutinis 22.29 USD 90.19%

Aukščiausias 29 USD

Žemiausias 16 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

160 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.